This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-27. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Sodium carbonate (soda) was produced by the Leblanc process until 1880, when the much cheaper Solvay process became available. BASF ceased to make its own and bought it from the Solvay company thereafter.
Shorter D-stem: To understand the role of the unusual long D-stem in tRNASec, artificial variants with shorter D-stems were put into E. coli. It turns out that these variants work faster than the standard version at regular temperatures but easily lose function at high temperatures. This suggests that the long D-stem evolved as an adaptation to high temperature. Removal of SelB and SECIS requirement: In 2013, a new kind of tRNA was artificially created by putting the acceptor stem and CUA anticodon of E. coli tRNASec on the backbone of E. coli tRNASer. This new tRNAUTu can be recognized by ordinary EF-Tu, removing the requirement for SelB and SECIS for elongation. However, about 40% of the insertions were serine instead of selenocystine, suggesting that SelA is not efficiently recognizing this tRNA. In 2014, directed evolution was used to greatly improve the ability of tRNAUTu to be recognized by SelA, achieving a version that results in no detected misincorporation of serine. This enables simple replacement of any residue by Sec in future protein engineering efforts. By 2018, the E. coli system has matured to be suitable for "industrial scale" production. In one case this was achieved by laborotaory evolution. In another case this was achieved by incorporating elements of allo-tRNAs. The tRNAUTu system was adapted to Saccharomyces cerevisiae (yeast), which has no natural selenocystine system, in 2023. A mixture of bacterial and mouse enzymes work on a modified yeast tRNASer, which is able to be recognized by eEF1A.
The US has used its dominant power to enforce the conventions in other countries, in ways that include making financial aid contingent on drug control efforts, and supplying economic and military support for drug intervention. The drug conventions do not explicitly prohibit, they establish control over a set of drugs. The personal use of illicit drugs is not outlawed, although possession is. Penalties are not specified, they are at the discretion of individual countries, and can range from mild to harsh. In practice, this flexibility has been used to create a prohibitionist, punitive war on drugs that is not explicitly required by the treaties. Negative effects of this hardline approach – increased violence and organized crime; human rights violations – have led to an increasing number of countries deviating from the regime. Deviation undermines the credibility of the drug conventions, which in turn, can weaken the entire system of UN international treaties.
Physical organic chemistry, a term coined by Louis Hammett in 1940, refers to a discipline of organic chemistry that focuses on the relationship between chemical structures and reactivity, in particular, applying experimental tools of physical chemistry to the study of organic molecules. Specific focal points of study include the rates of organic reactions, the relative chemical stabilities of the starting materials, reactive intermediates, transition states, and products of chemical reactions, and non-covalent aspects of solvation and molecular interactions that influence chemical reactivity. Such studies provide theoretical and practical frameworks to understand how changes in structure in solution or solid-state contexts impact reaction mechanism and rate for each organic reaction of interest.
Sources: en.wikipedia.org
The Unitized Group Ration (UGR) is a United States military ration used by the United States Armed Forces and Department of Defense (DoD). It is intended to sustain groups of American service members with access to a field kitchen, serving as a field ration and a garrison ration. It is the modern successor to several older alphabetized rations— the A-ration, B-ration, and T-ration—combining them under a single unified system. UGRs are designed to meet the Military Daily Recommended Allowance when averaged over a 5 to 10 day period, with each meal providing between 1,300 and 1,450 kcal. The UGR was introduced in 1999, and is currently known to be used by the U.S. Army, U.S. Marine Corps, U.S. Air Force, and National Guard. The U.S. Navy also reportedly uses the UGR for disembarked operations, using the Navy Standard Core Menu (NSCM) aboard naval vessels. The UGR's individual field and combat equivalent is the better-known Meal, Ready-to-Eat (MRE), with the First Strike Ration (FSR), Long Range Patrol (LRP), and Meal, Cold Weather (MCW) serving as specialized field equivalents.
Without proofreading, DNA replication is inherently somewhat error-prone, but by introducing error-prone polymerases, droplet-based PCR utilizes higher than normal mutation output to build a mutation library more quickly and efficiently than normal. This makes droplet-based PCR more attractive than slower, traditional PCR. In a similar application, highly multiplexed, microdroplet PCR has been developed that allows for the screening of large numbers of target sequences enabling applications such as bacterial identification. On-chip PCR allows for an excess of 15 x 15 multiplexing, which means that multiple target DNA sequences could be run on the same device at the same time. This multiplexing was made possible with immobilized DNA primer fragments placed in the base of the individual wells of the chips. Combining droplet-based PCR with polydimethylsiloxane (PDMS) devices has allowed for novel enhancements of droplet PCR as well as remedying some preexisting problems with droplet PCR including high liquid loss due to evaporation. Droplet-based PCR is highly sensitive to air bubbles as they create temperature differentials hindering DNA replication while also dislodging reagents from the replication chamber. Now, droplet-based PCR has been carried out in PDMS devices to transfer reagents into droplets through a PDMS layer in a more controlled manner that better maintains replication progress and stability than traditional valves.
==== Ingestion ==== While null in comparison to the concentrations found in indoor air, benzene, toluene, and methyl tert-butyl ether (MTBE) were found in samples of human milk and increase the concentrations of VOCs that we are exposed to throughout the day. A study notes the difference between VOCs in alveolar breath and inspired air suggesting that VOCs are ingested, metabolized, and excreted via the extra-pulmonary pathway. VOCs are also ingested by drinking water in varying concentrations. Some VOC concentrations were over the EPA's National Primary Drinking Water Regulations and China's National Drinking Water Standards set by the Ministry of Ecology and Environment.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.